Systems and methods for treating cancer and/or augmenting organ function
Systems, methods and devices for controlled sympathectomy procedures for neuromodulation in the treatment of subjects having neoplastic conditions are disclosed. Systems, methods, and devices for interventionally treating a cancerous tumor and cancer related pain are disclosed.
1. A composition, for use in blocking at least one of one or more nerves and one or more lymphatic ducts, comprising:
a neurolytic agent;
a sympathetic nerve selective neurotoxin for ablating a region surrounding a nutrient artery of a bone; and
an inflammatory agent;
wherein the neurolytic agent comprises ethanol;
wherein the inflammatory agent comprises one or more of poly(lactic-co-glycolic acid) (PLGA), polysaccharides, collagen, silica particles, carbon micro or nanoparticles, and microbeads; and
wherein the sympathetic nerve selective neurotoxin comprises at least one of 6-hydroxydopamine, ω-conotoxin, and bungarotoxin.
2. The composition of claim 1 , further comprising one or more of an ablative agent, a migration limiting agent and an inflammatory accelerating agent.
3. The composition of claim 1 , further comprising one or more of a medicament, a denervating agent, a sympathetic denervating agent, a parasympathetic nerve specific denervating agent, a neuroblocking agent, and a highly specific neuroblocking agent.
4. A method comprising treating at least one of a tumor, metastasis migration and cancer pain utilizing the composition of claim 1 .
5. A method comprising blocking at least one of one or more nerves and one or more lymphatic ducts traveling along a lumen coupling a first organ to at least a second organ in a body utilizing the composition of claim 1 .
6. A method comprising treating neurogenic pathways associated with cancer progression utilizing the composition of claim 1 .
7. A method comprising altering a structure of a perineural sheath of at least one of the one or more nerves utilizing the composition of claim 1 .
8. A method comprising performing architectural destruction of at least one of nerve tissue and lymphatic ductal tissue via inflammation utilizing the composition of claim 1 .
9. A method comprising forming scar tissue along at least one of the one or more nerves and the one or more lymphatic ducts utilizing the composition of claim 1 .
10. The composition of claim 1 , wherein the inflammatory agent comprises PLGA.
11. The composition of claim 1 , wherein the inflammatory agent comprises polysaccharides.
12. The composition of claim 1 , wherein the inflammatory agent comprises collagen.
13. The composition of claim 1 , wherein the inflammatory agent comprises silica particles.
14. The composition of claim 1 , wherein the inflammatory agent comprises carbon micro or nanoparticles.
15. The composition of claim 1 , wherein the inflammatory agent comprises microbeads.
16. The composition of claim 15 , wherein the microbeads comprise silica beads.
17. The composition of claim 15 , wherein the microbeads comprise PLGA beads.